Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Biotechnology

Healthcare
$19.17 -1.71%

-$0.22 today

Market cap
$676.80M
Beta
1.08
P/E (TTM)
-36.5
EPS (TTM)
-$0.24
52W Low $7.59High $14.24

Volume 0.00M

Average 0.00M

FRX.TO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Fennec Pharmaceuticals Inc.TSX: FRX.TO

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $15.07M rose 72.2% year over year, ahead of the +65.5% change in trailing-twelve-month revenue. Sequentially, it rose 7.7% from the prior quarter. Over 3 fiscal years it compounded at +207.5% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $74.03M (+65.8%) for the fiscal year ending Dec 2026, a step up from the -6.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.07M+7.7% QoQ
Last fiscal yearDec 2025
$44.64M-6.1% YoY
LTMMar 2026
$51.17M+65.5% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+72.2%+67.8%-4.4 pp
1 year-6.1%+65.8%+71.9 pp
3-year CAGR+207.5%+48.9%-158.6 pp
5-year CAGR+40.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
44.64M USD
Year-over-year change
-6.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How FRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +65.5% is the highest of 6, against a peer median of +15.6%.
  • Over three fiscal years its annual growth of +207.5% compares with a peer median of -0.9%.
FRX.TO Competitors
Revenue for FRX.TO and competitors
Company Period LTM YoY 3-year CAGR
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$310.92M CAD+15.6%-5.1%
DR.TOMedical Facilities CorporationLTM Mar 2026$305.39M USD+0.1%-15.2%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$274.19M CAD+41.3%—
TSND.TOTerrAscend Corp.LTM Mar 2026$261.74M USD-8.7%+3.3%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$51.17M USD+65.5%+207.5%
PRN.TOProfound Medical Corp.LTM Mar 2026$18.76M USD+64.7%+34.8%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$0 USD——
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$0 CAD——
Peer median (excluding FRX.TO) —+15.6%-0.9%

Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.54M21.25M47.54M44.64M
Cost of Revenue086K1.26M3.18M3.76M
Gross Profit01.45M19.99M44.35M40.88M
Gross Margin—94.4%94.1%93.3%91.6%
Research & Development4.98M3.53M56K307K254.38K
Selling, General & Admin12.24M20.51M32.71M41.48M46.91M
Operating Expenses17.22M24.04M32.76M41.79M47.22M
Depreciation & Amortization17.22M149K287K800K103K
EBITDA(17.19M)(22.74M)(12.65M)4.8M(7.45M)
EBITDA Margin—-1481.2%-59.5%10.1%-16.7%
Operating Income(17.22M)(22.59M)(12.77M)2.57M(6.35M)
Operating Margin—-1471.6%-60.1%5.4%-14.2%
Interest Income54K195K441K1.68M800.78K
Interest Expense126K978K3.39M4.07M2.18M
Other Income / Expenses(123K)(1.13M)(3.27M)(2.64M)(3.29M)
Income Before Tax(17.35M)(23.71M)(16.05M)(71K)(9.64M)
Pre-Tax Margin—-1544.9%-75.5%-0.1%-21.6%
Income Tax Expense110K147K0365K106K
Net Income(17.46M)(23.86M)(16.05M)(436K)(9.74M)
Net Margin—-1554.5%-75.5%-0.9%-21.8%
EPS (Basic)(0.67)(0.91)(0.60)(0.02)(0.34)
EPS (Diluted)(0.67)(0.91)(0.60)(0.02)(0.34)
Weighted Avg Shares25.89M26.28M26.57M21.8M28.58M
Weighted Avg Shares (Diluted)26.01M26.28M26.57M27.3M28.58M

Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$19.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.